Armistice Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Armistice Capital’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-60,000	Closed	-$1.67M	–	83
2017 Q4	$1.67M	Buy	+60,000	New	+$1.86M	0.17%	57
2017 Q3	–	Sell	-160,000	Closed	-$3.55M	–	81
2017 Q2	$3.55M	Sell	160,000 -320,000	-67%	-$2.52M	0.45%	47
2017 Q1	$2.83M	Buy	+480,000	New	+$3.47M	0.58%	38

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital's AVEO Position: Q1 2018 in Review

Armistice Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2018, closing a stake of 60,000 shares — an estimated $1.67M sold.

Armistice Capital first reported a position in AVEO in Q1 2017 and held it in 3 quarters. The position peaked at $3.55M in Q2 2017. 90 funds tracked by Wall St. Rank hold AVEO as of Q1 2018.

Armistice Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Armistice Capital sold 60,000 AVEO Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.67M.
Armistice Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
Armistice Capital's AVEO Pharmaceuticals, Inc. position peaked at $3.55M in Q2 2017.
90 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2018.

Based on Armistice Capital's 13F filing for Q1 2018, filed 15 May 2018.